|
Summary of the significant, false discovery rate adjusted, and cross-validated ADRA2C and ADRB1 polymorphism effects and interactions on age of onset, LVmass, LVEF, and heart failure survival |
||||||||
| ED (N = 655) |
||||||||
| Age of Onset |
LVMass Adj* |
LVEF Adj** |
Survival |
|||||
|
|
||||||||
| SNP Main Effects |
SNP-SNP Interaction |
SNP Main Effects |
SNP_SNP Interaction |
SNP Main Effects |
SNP_SNP Interaction |
SNP Main Effects |
SNP_SNP Interaction |
|
|
|
||||||||
| Number of tests |
22 |
209 |
22 |
200 |
22 |
204 |
22 |
231 |
| P < 0.10 |
2 |
24 |
1 |
8 |
2 |
16 |
4 |
50 |
| FDR (<0.30) |
0 |
0 |
0 |
0 |
2 |
0 |
4 |
44 |
| Cross Validation*** |
0 |
0 |
0 |
0 |
1 |
0 |
3 |
10 |
| FDR and Cross-validation |
0 |
0 |
0 |
0 |
1 |
0 |
2 |
6 |
|
* LVMass was adjusted for age of onset, sex, height, weight, hypertension ** LVEF was adjusted for age of onset, sex *** For survival analysis, Risk Index was used to cross-validate, P-value for Cox model with Risk Index <0.1 is considered as crossvalidated. For continuous outcomes, 4-fold CV was used. Press-Rsquared >0.005 (SNP univ model) or Press-Rsquared for full model >0 and Press-Rsquared Difference between full model and submodel >0.005 (Epistasis) is considered to be crossvalidated for interaction. | ||||||||
Kardia et al. BMC Medical Genetics 2008 9:93 doi:10.1186/1471-2350-9-93 |
||||||||